Research Topics
Species | Melanie S JoySummaryAffiliation: University of North Carolina Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study designHoward Trachtman
Cohen Children s Medical Center of New York, North Shore Long Island Jewish Health System, New Hyde Park, NY, USA
BMC Nephrol 12:8. 2011..There is a need for a flexible Phase II study design which will test such novel antifibrotic strategies in order to identify agents suitable for phase III testing...- Impact of glomerular kidney diseases on the clearance of drugsMelanie S Joy
Division of Nephrology and Hypertension, Department of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, CB 7155, 7005 Burnett Womack Building, Chapel Hill, NC 27599 7155, USA
J Clin Pharmacol 52:23S-34S. 2012..Recommendations are provided for the design of future studies of drugs in the glomerulonephritis population and for inclusion of patients with urinary protein excretion in studies that assess drug pharmacokinetics... - Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicityMelanie S Joy
Division of Nephrology and Hypertension, University of North Carolina School of Medicine, UNC Kidney Center, CB 7155, 7005 Burnett Womack Building, Chapel Hill, NC 27599 7155, USA
Nephrol Dial Transplant 22:1963-8. 2007..The role of drug transporters (P-glycoprotein) and drug metabolizing enzymes (cytochrome P450) as predisposing factors toward nephrotoxicity or its prevention has not been thoroughly examined... - Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney diseaseMelanie S Joy
Division of Nephrology and Hypertension, UNC Kidney Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 7155, USA
Pharmacotherapy 27:734-44. 2007.... - Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatmentMelanie S Joy
School of Medicine, Division of Nephrology and Hypertension, UNC Kidney Center, Univerisity of North Carolina, Chapel Hill, NC 27599 7155, USA
J Manag Care Pharm 13:397-411. 2007..The number of patients who will be identified and prescribed therapies for complications such as secondary hyperparathyroidism (SHPT) is greater than initially proposed... - Nephrology pharmacy: historical reflections and future challengesMelanie S Joy
Division of Nephrology and Hypertension, School of Medicine, The University of North Carolina, Chapel Hill, NC, USA
Ann Pharmacother 41:1884-6. 2007 - Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patientsMelanie S Joy
Division of Nephrology and Hypertension, School of Medicine, University of North Carolina Kidney Center, University of North Carolina, Chapel Hill, NC 27599, USA
Ann Pharmacother 42:9-15. 2008..The effects of statins (eg, atorvastatin) on altering nontraditional lipoprotein measures in dialysis patients have not been extensively investigated... - Pharmacokinetics of mycophenolic acid in patients with lupus nephritisMelanie S Joy
University of North Carolina Kidney Center, Chapel Hill, North Carolina 27599 7155, USA
Pharmacotherapy 29:7-16. 2009.... - CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseasesMelanie S Joy
Division of Nephrology and Hypertension, School of Medicine, UNC Kidney Center, University of North Carolina, Chapel Hill, NC, USA
Eur J Clin Pharmacol 65:947-53. 2009..It is metabolized by cytochrome P450 (CYP) 2C9 to active E-3174. Single nucleotide polymorphisms in CYP2C9 that reduce catalytic activity could reduce clinical benefits... - Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritisMelanie S Joy
School of Medicine, UNC Kidney Center, University of North Carolina, Chapel Hill, NC, USA
Eur J Clin Pharmacol 66:1119-30. 2010..The role of pharmacogenomics, clinical and demographic parameters in pharmacokinetic predictions was evaluated in patients receiving mycophenolic acid (MPA)... - Lanthanum carbonateMelanie S Joy
School of Medicine, Division of Nephrology, University of North Carolina, Carolina Kidney Center, Chapel Hill, NC 27599 7155, USA
Ann Pharmacother 40:234-40. 2006..To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of lanthanum carbonate, a phosphate binder for chronic kidney disease (CKD)... - Long-term glycemic control measurements in diabetic patients receiving hemodialysisMelanie S Joy
Division of Nephrology and Hypertension, University of North Carolina, School of Medicine, Chapel Hill, NC 27599 7155, USA
Am J Kidney Dis 39:297-307. 2002..Thus, diabetic patients receiving hemodialysis may have long-term BG that are more properly controlled than previously determined, reducing their risks of the macro- and microvascular complications of diabetes mellitus... - Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemiaMelanie S Joy
University of North Carolina, School of Medicine, Division of Nephrology and Hypertension, Chapel Hill, NC 27599 7155, USA
Am J Kidney Dis 42:96-107. 2003.... - Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoproteinMelanie S Joy
Division of Nephrology and Hypertension, Carolina Kidney Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
Pharmacotherapy 25:779-89. 2005.... - Calcimimetics and the treatment of primary and secondary hyperparathyroidismMelanie S Joy
Division of Nephrology and Hypertension, School of Medicine, University of North Carolina, Chapel Hill, NC, USA
Ann Pharmacother 38:1871-80. 2004..To review the mechanism of action, development, and clinical application of the calcimimetic compounds being investigated for the treatment of primary and secondary hyperparathyroidism (HPT)... - Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitisMelanie S Joy
School of Medicine, University of North Carolina UNC at Chapel Hill, Chapel Hill, NC 27599, USA
Ann Pharmacother 43:1020-7. 2009..Mycophenolic acid (MPA) is used off-label to treat many forms of glomerulonephritis... - Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysisKimberly A Dornbrook-Lavender
Department of Pharmacotherapy, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA
Pharmacotherapy 25:335-44. 2005..A larger study is necessary to provide definitive information on the effects of atorvastatin on LDL phenotype and CRP in patients with kidney disease... - Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control studySofia Lionaki
UNC Kidney Center and Division of Nephrology and Hypertension, 7009 Burnett Womack, CB 7155, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 5074, USA
Nephrol Dial Transplant 22:3508-15. 2007..This association was evaluated in a southeastern US population-based case-control study... - Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study groupMelanie S Joy
UNC Kidney Center and Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Am J Kidney Dis 55:50-60. 2010..Antifibrotic agents, such as tumor necrosis factor alpha antagonists, are a promising strategy to slow or halt the decline in renal function, based on preclinical and clinical data... - Darbepoetin alfa: a novel erythropoiesis-stimulating proteinMelanie S Joy
School of Medicine, Division of Nephrology and Hypertension, University of North Carolina, CB 7155, 348 MacNider Bldg, Chapel Hill, NC 27599 7155, USA Melanie_
Ann Pharmacother 36:1183-92. 2002..To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of darbepoetin alfa... - A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitisMelanie S Joy
Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
Nephrol Dial Transplant 20:2725-32. 2005..CONCLUSIONS: MMF is a reasonable option in the treatment of non-life-threatening recurrent or resistant vasculitis and may obviate the immediate need for recurrent use of cytotoxic agents... - Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidismNora Franceschini
University of North Carolina, School of Medicine, Division of Nephrology and Hypertension, CB 7155, 348 MacNider Building, Chapel Hill, NC 27599 7155, USA
Expert Opin Investig Drugs 12:1413-21. 2003..This drug has a favourable pharmacokinetic profile compared to its precursors and will prove useful as an additional/alternative agent in patients with primary and secondary HPT... - Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study GroupMelanie S Joy
University of North Carolina at Chapel Hill, University of North Carolina Kidney Center and Division of Nephrology and Hypertension, Chapel Hill, NC, USA
Clin J Am Soc Nephrol 4:39-47. 2009..The primary goal was assessment of safety, tolerability, and pharmacokinetics (PK) of rosiglitazone... - Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia careRichard A Hansen
University of North Carolina at Chapel Hill, School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, Chapel Hill, NC 27599, USA
Res Social Adm Pharm 5:143-53. 2009..Anemia is common in chronic kidney disease (CKD), and suboptimal management of anemia can lead to serious health complications and poor quality of life (QOL)... - A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysisWilliam F Finn
Department of Medicine, University of North Carolina, Chapel Hill, NC 27599-7155, USA
Curr Med Res Opin 21:657-64. 2005..CONCLUSION: Lanthanum carbonate is well tolerated and is effective for the long-term maintenance of serum phosphorus control in patients with end-stage renal disease... - Cutaneous and systemic manifestations of drug-induced vasculitisSandra M ten Holder
Division of Nephrology and Hypertension, School of Medicine, University of North Carolina, CB #7155, 348 MacNider Bldg, Chapel Hill, NC 27599-7155, USA
Ann Pharmacother 36:130-47. 2002..CONCLUSIONS: Clinicians need to be suspect of drug-induced vasculitis to enable prompt diagnosis and treatment. This should improve patient outcomes based on the data referenced for this article... - Caring for patients with chronic kidney disease: a joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical PharmacyAlan J Zillich
Purdue Pharmacy Programs, Purdue University School of Pharmacy, Indianapolis, Indiana 46202, USA
Pharmacotherapy 25:123-43. 2005..Collectively, many opportunities exist for pharmacists who practice in the primary care setting to improve the care of patients with CKD... - Clinical pharmacists as multidisciplinary health care providers in the management of CKD: a joint opinion by the Nephrology and Ambulatory Care Practice and Research Networks of the American College of Clinical PharmacyMelanie S Joy
Am J Kidney Dis 45:1105-18. 2005
Research Grants
- Pharmacokinetics & Genomics in Glomerular DiseasesMELANIE JOY; Fiscal Year: 2007..The selection of collaborators with expertise in the areas of this grant will enhance the career development of Dr. Joy. ..